509 related articles for article (PubMed ID: 30126053)
1. Persistent muscle-invasive bladder cancer after neoadjuvant chemotherapy: an analysis of Surveillance, Epidemiology and End Results-Medicare data.
Lane G; Risk M; Fan Y; Krishna S; Konety B
BJU Int; 2019 May; 123(5):818-825. PubMed ID: 30126053
[TBL] [Abstract][Full Text] [Related]
2. Oncologic Outcomes for Patients with Residual Cancer at Cystectomy Following Neoadjuvant Chemotherapy: A Pathologic Stage-matched Analysis.
Bhindi B; Frank I; Mason RJ; Tarrell RF; Thapa P; Cheville JC; Costello BA; Pagliaro LC; Karnes RJ; Thompson RH; Tollefson MK; Boorjian SA
Eur Urol; 2017 Nov; 72(5):660-664. PubMed ID: 28545841
[TBL] [Abstract][Full Text] [Related]
3. Is neoadjuvant chemotherapy for pT2 bladder cancer associated with a survival benefit in a population-based analysis?
Mazzone E; Knipper S; Mistretta FA; Tian Z; Preisser F; Gallina A; Soulieres D; Tilki D; Montorsi F; Shariat SF; Saad F; Briganti A; Wisnivesky J; Karakiewicz PI
Cancer Epidemiol; 2019 Feb; 58():83-88. PubMed ID: 30528834
[TBL] [Abstract][Full Text] [Related]
4. Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy.
Pietzak EJ; Zabor EC; Bagrodia A; Armenia J; Hu W; Zehir A; Funt S; Audenet F; Barron D; Maamouri N; Li Q; Teo MY; Arcila ME; Berger MF; Schultz N; Dalbagni G; Herr HW; Bajorin DF; Rosenberg JE; Al-Ahmadie H; Bochner BH; Solit DB; Iyer G
Eur Urol; 2019 Feb; 75(2):231-239. PubMed ID: 30290956
[TBL] [Abstract][Full Text] [Related]
5. Progression of Disease after Bacillus Calmette-Guérin Therapy: Refining Patient Selection for Neoadjuvant Chemotherapy before Radical Cystectomy.
Hensley PJ; Bree KK; Campbell MT; Alhalabi O; Kokorovic A; Miest T; Nogueras-Gonzalez GM; Gao J; Siefker-Radtke AO; Guo CC; Navai N; Dinney CP; Kamat AM
J Urol; 2021 Nov; 206(5):1258-1267. PubMed ID: 34184926
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer in the Current Real World Setting in the USA.
Hanna N; Trinh QD; Seisen T; Vetterlein MW; Sammon J; Preston MA; Lipsitz SR; Bellmunt J; Menon M; Choueiri TK; Abdollah F
Eur Urol Oncol; 2018 May; 1(1):83-90. PubMed ID: 31100232
[TBL] [Abstract][Full Text] [Related]
7. Delays in radical cystectomy for muscle-invasive bladder cancer.
Chu AT; Holt SK; Wright JL; Ramos JD; Grivas P; Yu EY; Gore JL
Cancer; 2019 Jun; 125(12):2011-2017. PubMed ID: 30840335
[TBL] [Abstract][Full Text] [Related]
8. Comparison of trimodality therapy and neoadjuvant chemotherapy combined with radical cystectomy for the survival of muscle-invasive bladder cancer: a population-based analysis.
Zhou YX; Hu QC; Zhu YJ; Mu XL; Liu JY; Chen Y
Eur J Med Res; 2023 Oct; 28(1):422. PubMed ID: 37822001
[TBL] [Abstract][Full Text] [Related]
9. Discerning Patterns and Quality of Neoadjuvant Chemotherapy Use Among Patients with Muscle-invasive Bladder Cancer.
Huo J; Ray-Zack MD; Shan Y; Chamie K; Boorjian SA; Kerr P; Jana B; Freedland SJ; Kamat AM; Mehta HB; Williams SB
Eur Urol Oncol; 2019 Sep; 2(5):497-504. PubMed ID: 31411998
[TBL] [Abstract][Full Text] [Related]
10. Superior efficacy of neoadjuvant chemotherapy and radical cystectomy in cT3-4aN0M0 compared to cT2N0M0 bladder cancer.
Hermans TJN; Voskuilen CS; Deelen M; Mertens LS; Horenblas S; Meijer RP; Boormans JL; Aben KK; van der Heijden MS; Pos FJ; de Wit R; Beerepoot LV; Verhoeven RHA; van Rhijn BWG
Int J Cancer; 2019 Mar; 144(6):1453-1459. PubMed ID: 30155893
[TBL] [Abstract][Full Text] [Related]
11. Randomised phase III study of neoadjuvant chemotherapy with methotrexate, doxorubicin, vinblastine and cisplatin followed by radical cystectomy compared with radical cystectomy alone for muscle-invasive bladder cancer: Japan Clinical Oncology Group Study JCOG0209.
Kitamura H; Tsukamoto T; Shibata T; Masumori N; Fujimoto H; Hirao Y; Fujimoto K; Kitamura Y; Tomita Y; Tobisu K; Niwakawa M; Naito S; Eto M; Kakehi Y;
Ann Oncol; 2014 Jun; 25(6):1192-8. PubMed ID: 24669010
[TBL] [Abstract][Full Text] [Related]
12. Meta-analysis of neoadjuvant chemotherapy compared to radical cystectomy alone in improving overall survival of muscle-invasive bladder cancer patients.
Hamid ARAH; Ridwan FR; Parikesit D; Widia F; Mochtar CA; Umbas R
BMC Urol; 2020 Oct; 20(1):158. PubMed ID: 33054762
[TBL] [Abstract][Full Text] [Related]
13. Use of Neoadjuvant Chemotherapy in Elderly Patients With Muscle-Invasive Bladder Cancer: A Population-Based Study, 2006-2017.
Posielski N; Koenig H; Ho O; Porter C; Flores JP
Oncology (Williston Park); 2022 Jan; 36(1):21-33. PubMed ID: 35089670
[TBL] [Abstract][Full Text] [Related]
14. Delaying Radical Cystectomy After Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer is Associated with Adverse Survival Outcomes.
Boeri L; Soligo M; Frank I; Boorjian SA; Thompson RH; Tollefson M; Quevedo FJ; Cheville JC; Karnes RJ
Eur Urol Oncol; 2019 Jul; 2(4):390-396. PubMed ID: 31277775
[TBL] [Abstract][Full Text] [Related]
15. Sarcomatoid Urothelial Carcinoma Is Associated With Limited Response to Neoadjuvant Chemotherapy and Poor Oncologic Outcomes After Radical Cystectomy.
Sekar RR; Diamantopoulos LN; Bakaloudi DR; Khaki AR; Grivas P; Winters BR; Vakar-Lopez F; Tretiakova MS; Psutka SP; Holt SK; Gore JL; Lin DW; Schade GR; Hsieh AC; Lee JK; Yezefski T; Schweizer MT; Cheng HH; Yu EY; True LD; Montgomery RB; Wright JL
Clin Genitourin Cancer; 2023 Aug; 21(4):507.e1-507.e14. PubMed ID: 37150667
[TBL] [Abstract][Full Text] [Related]
16. Contemporary use and survival after perioperative systemic chemotherapy in patients with locally advanced non-metastatic urothelial carcinoma of the bladder treated with radical cystectomy.
Mazzone E; Nazzani S; Knipper S; Tian Z; Preisser F; Gallina A; Soulières D; Tilki D; Montorsi F; Shariat SF; Saad F; Briganti A; Wisnivesky J; Karakiewicz PI
Eur J Surg Oncol; 2019 Jul; 45(7):1253-1259. PubMed ID: 30755341
[TBL] [Abstract][Full Text] [Related]
17. The effect of the time interval between diagnosis of muscle-invasive bladder cancer and radical cystectomy on staging and survival: A Netherlands Cancer Registry analysis.
Bruins HM; Aben KK; Arends TJ; van der Heijden AG; Witjes AJ
Urol Oncol; 2016 Apr; 34(4):166.e1-6. PubMed ID: 26705102
[TBL] [Abstract][Full Text] [Related]
18. Occult lymph node metastases in patients with carcinoma invading bladder muscle: incidence after neoadjuvant chemotherapy and cystectomy vs after cystectomy alone.
Mertens LS; Meijer RP; Meinhardt W; van der Poel HG; Bex A; Kerst JM; van der Heijden MS; Bergman AM; Horenblas S; van Rhijn BW
BJU Int; 2014 Jul; 114(1):67-74. PubMed ID: 24053889
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant Chemotherapy vs Observation for Patients With Adverse Pathologic Features at Radical Cystectomy Previously Treated With Neoadjuvant Chemotherapy.
Seisen T; Jamzadeh A; Leow JJ; Rouprêt M; Cole AP; Lipsitz SR; Kibel AS; Nguyen PL; Sun M; Menon M; Bellmunt J; Choueiri TK; Trinh QD
JAMA Oncol; 2018 Feb; 4(2):225-229. PubMed ID: 28837718
[TBL] [Abstract][Full Text] [Related]
20. Cystectomy vs. bladder preservation after neoadjuvant chemotherapy in muscle-invasive bladder cancer: A tertiary medical center experience.
Halabi IE; Husseini ZE; Haibe Y; Charafeddine M; Mukherji D; Temraz S; Bulbul M; Khauli R; Nasr R; Wazzan W; Hajj AE; Geara F; Shamseddine A
Cancer Treat Res Commun; 2020; 25():100222. PubMed ID: 33080450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
